Epitomics, Inc.

Epitomics, Inc. develops and supplies innovative antibodies and related products that enhance research capabilities in the life sciences sector, facilitating advancements in various scientific fields. Epitomics, Inc. specializes in the development of monoclonal antibodies and was founded in 2002 in Burlingame, US.

It was acquired by Abcam plc in March 2012 for USD 155 mn. The company has engaged in three deals since its inception, with the most recent deal date being March 5, 2012. Its founder's history is not publicly detailed, and there are no known subsidiaries or parent companies associated with Epitomics. Epitomics offers a range of high-quality antibodies, proteins, and reagents tailored to the life sciences research community.

Its product line includes more than 37,000 recombinant antibodies utilized in various applications such as Western blotting and immunohistochemistry. The company also provides cellular assay kits like the DCFDA/H2DCFDA Cellular ROS Assay Kit and SimpleStep ELISA® kits designed for specific protein quantification, catering primarily to academic and commercial researchers worldwide. Epitomics generates revenue through direct sales to research institutions, academic laboratories, and biotech firms. The company's sales model enables researchers to purchase products and assay kits, enhancing accessibility to necessary research tools.

Their pricing strategy ensures that researchers can acquire high-quality products at competitive rates, which helps maintain Epitomics's solid reputation in the life sciences sector. Following its acquisition by Abcam plc, Epitomics is positioned to leverage its capabilities for future growth. The integration into Abcam is expected to support the launch of new products, although specific release dates have not been detailed. The company intends to expand its market presence, particularly in North America, Europe, and Asia-Pacific, to meet the demands of academic and commercial researchers.

The USD 155 mn from the Trade Sale in March 2012 is anticipated to bolster these initiatives, facilitating product development and market expansion.